Key Model for Drug Development in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial lung disease that is confined to the lungs and is prevalent in middle-aged and elderly people, with lung histology and/or high-resolution CT (HRCT) of the chest characterizing it as a generalized interstitial pneumonitis (UIP) of unknown etiology.With a mean survival of 2.8 years after diagnosis, and with a mortality rate higher than that of most tumors, IPF has been called a “tumor-like disease”. IPF has been called a “tumor-like disease”.We have established a stable model of idiopathic pulmonary fibrosis, which is suitable for preclinical studies of drugs for idiopathic pulmonary fibrosis and evaluation of new drugs.
Please contact us for your project needs and to experience more of our professional services.
Our services
Model classification | Model Name | Animal species |
Idiopathic pulmonary fibrosis | Unilateral idiopathic pulmonary fibrosis model induced by a single bleomycin (BLM) dose | Rat |
Bilateral idiopathic pulmonary fibrosis model induced by a single bleomycin (BLM) dose | Mice，rats | |
Unilateral idiopathic pulmonary fibrosis model induced by repeatedly bleomycin (BLM) dose | Rat | |
Bilateral idiopathic pulmonary fibrosis model induced by repeatedly bleomycin (BLM) do | Rat |
Case sharing
BLM induced mouse lung fibrosis model
BLM induced rat unilateral lung fibrosis model
Silicon induced lung fibrosis model on rodents
